Novo Nordisk is actively lobbying to maintain Medicaid coverage for its weight-loss drug Wegovy, facing resistance from some U.S. states concerned about costs. This situation highlights the ongoing debate about the affordability and accessibility of new pharmaceutical treatments, particularly for chronic conditions. Positive outcomes could be continued patient access to effective treatments. Negative impacts include potential strain on state budgets and debates over healthcare spending priorities. The pharmaceutical industry is heavily influenced by healthcare policy, government regulations, and lobbying efforts. Political decisions regarding healthcare funding and drug pricing are critical external factors.